Ophthalmic Devices Market Forecast 2016-2026

06 September 2016
Pharma

A new report by visiongain predicts that the Ophthalmic Devices market will reach $22.84bn in 2020. This forecast and others appear in Ophthalmic Devices Market Forecast 2016-2026: Clarifying Vision – Prospects and Developments in Ophthalmic Surgical Devices, Diagnostics and Monitoring, and Vision Care published in May 2016. Visiongain is a business information provider based in London, UK.
The report examines the current and future trends in the Ophthalmic Devices market with particular focus on recent pivotal developments in the sector involving pipeline paradigm-shifting products and the major acquisitions that have taken place between large ophthalmics companies in the last few years.

Ophthalmic Devices are instruments or similar articles intended for use in diagnosis, treatment, prevention or monitoring of eye diseases or conditions. This includes devices placed directly on the surface of the eye or inserted into the eye. The Ophthalmic Devices market encompasses the following product segments: Diagnostics and Monitoring devices, Vision Care and Surgical devices.

As the global population ages, there is an increased incidence of conditions that precipitate poor vision. In addition, there’s an increased demand from populations in both emerging and developed economies to improve ocular health and sight. The highly competitive ophthalmic devices market is increasingly expected to innovate in order to meet these demands in a safe manner. Pipeline developments of contact and intraocular lenses include more sophisticated technologies to improve comfort and also possess enhanced features such as blood glucose monitoring, which is anticipated to be the next paradigm shift in ophthalmic device and eye care.

In this report, we examine in detail the factors which are driving the Ophthalmic Devices market growth and the key companies currently operating in the ophthalmic devices market including their product pipelines. We also examine key national markets and discuss trends and variations within these markets, alongside an analysis of ophthalmic devices. The Ophthalmic Devices categories examined in this report are: Vision Care, Surgical Devices, Diagnostics and Monitoring Devices. National Markets focused on are the US, China, Japan, EU5 (Germany, UK, Italy, France and Spain), Brazil, Russia, India and South Korea.

Using both primary and secondary research, forecasts have been built for the major submarkets, leading products and leading national and regional markets, accompanied by text giving a thorough explanation of events thought to shape the market currently and in the future.

Also included is analysis of the current leading players in the Ophthalmic Devices Market. Historical financial performance is analysed, where available, along with a breakdown of each company’s leading products, and recent merger & acquisition information, with an analysis of news that may influence the course of the company.

Visiongain’s report provides revenue forecasts to 2026 for the Ophthalmic Devices market and its leading devices, submarkets and international markets. The report discusses selected leading companies which hold significant shares of the market. These companies include Alcon, Abbott Medical Optics, Bausch and Lomb, Johnson and Johnson, Nidek, Hoya, STAAR, Carl Zeiss AG Meditec, TopCon, and Haag-Streit Holding Ag. Visiongain’s report also discusses key economic points, commercial news, and analysis of strengths, weaknesses, opportunities and threats.

The Ophthalmic Devices Market Forecast 2016-2026: Clarifying Vision—Prospects and Developments in Ophthalmic Surgical Devices, Diagnostics and Monitoring, and Vision Care report adds to visiongain’s range of analytical reports on industries and markets in healthcare.

For an executive summary please contact:
Email: Sara Peerun on sara.peerun@visiongainglobal.com
Tel: +44 (0) 20 7336 6100

Notes for Editors

If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. From its head office in London, UK, visiongain produces a range of newsletters, business reports and e-zines covering current affairs and market trends in the Energy, Telecoms, Pharmaceutical, Defence, and Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high quality, original analyses to inform their strategic decisions.

Recent News

“Oncology remains the largest disease area in the pharmaceutical business. The oncology market is dominated by big pharma companies and high price labels” says Visiongain report

Although price is still the most important competitive advantage for a biosimilar company, current discount rates are not enough to automatically convince the key stakeholders of a biosimilar’s value.

10 September 2019

Read

“Anti-Infective Agents market set to grow to $141bn by 2024” says new Visiongain report

The global anti-infective agents market is one that is driven by innovation. This is vital for maintaining the rich pipeline of anti-infective agents seen in the market today.

09 September 2019

Read

“Global thyroid gland disorder treatment market is anticipated to grow at a lucrative CAGR of 3.6% and anticipated to reach USD 3.21 Billion by 2029”, says Visiongain report.

Thyroid disease is one of today’s most prevalent hormonal illnesses. Hyperthyroidism, hypothyroidism, and thyroid nodules are the most common thyroid gland disorders.

05 September 2019

Read

“Global somatostatin analogs market is anticipated to grow at a lucrative CAGR of 5.3% and anticipated to reach USD 4.78 Bn by 2029”, says Visiongain report.

Somatostatin was used to diagnose gastrointestinal tract tumors and acromegaly in the clinical environment.

05 September 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever